

THURSDAY, APRIL 14, 2011

Apella Event Space at Alexandria Center

7:30 a.m.

REGISTRATION

8:00 a.m.

WELCOME

Joel S. Marcus, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments

8:15 a.m.

OPENING REMARKS

John Mendelsohn, MD, President, The University of Texas MD Anderson Cancer Center

9:00 a.m.

SESSION 1: Global Issues Impacting the Discovery and Development of Cost-Effective Cancer Therapies and Diagnostics

MODERATOR:

Tim Anderson, MD, Global Pharmaceuticals Analyst, Sanford C. Bernstein and Co., LLC

PANELISTS:

David Epstein, MBA, Division Head, Novartis Pharmaceuticals Corp.; Member of the Executive Committee, Novartis AG

Dennis Gillings, CBE, PhD, Chairman & Chief Executive Officer, Quintiles Transnational Corp.

Carl L. Gordon, PhD, CFA, Founding General Partner, OrbiMed Advisors, LLC

Xi-Shan Hao, MD, FACS, President, Chinese Anti-Cancer Association; President, Tianjin Medical University; President, Tianjin Medical University Cancer Institute and Hospital

Jeremy M. Levin, DPhil, MB, BChir, Senior Vice President, Strategy, Alliances and Transactions, Bristol-Myers Squibb Co.

Janet Woodcock, MD, Director, Center for Drug Evaluation & Research, Food and Drug Administration

Lynne Zydowsky, PhD, President, Zydowsky Consultants LLC; Advisor, Alexandria Real Estate Equities, Inc.

10:30 a.m.

BREAK

11:00 a.m.

SESSION 2: Financing the Next Wave of Innovative Cancer Therapies and Diagnostics

MODERATOR:

Carl Goldfischer, MD, Investment Partner & Managing Director, Bay City Capital LLC

PANELISTS:

N. Anthony Coles, MD, MPH, President & Chief Executive Officer, Onyx Pharmaceuticals, Inc.

Mikael Dolsten, MD, PhD, President, Worldwide Research and Development, Senior Vice President, Pfizer Inc.

K. Peter Hirth, PhD, Chief Executive Officer, Plexxikon Inc.

Patrick J. Mahaffy, President & Chief Executive Officer, Clovis Oncology, Inc.

Stephen Sands, Managing Director & Global Co-Head of Healthcare Investment Banking, Lazard Freres & Co. LLC

12:30 p.m.

LUNCH & KEYNOTE

Exploring Innovation in Clinical Trials for the Next Generation of Cancer Therapies and Diagnostics

MODERATOR:

Robert Bazell, Chief Science & Health Correspondent, NBC News

KEYNOTE SPEAKERS:

Donald A. Berry, PhD, Professor, The University of Texas MD Anderson Cancer Center

Laura Esserman, MD, MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology & Associate Director, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Janet Woodcock, MD, Director, Center for Drug Evaluation & Research, Food and Drug Administration.

2:00 p.m.

SESSION 3: The Era of Collaboration: Why Collaboration Is the Path to Innovation

MODERATOR:

Martin J. Murphy, DMedSc, PhD, Chief Executive Officer, CEO Roundtable on Cancer

PANELISTS:

Gregory A. Curt, MD, U.S. Medical Science Lead for Emerging Products, AstraZeneca Oncology

James H. Doroshow, MD, FACP, Director, Division of Cancer Treatment & Diagnosis, National Cancer Institute

Richard B. Gaynor, MD, Vice President, Product Development / Medical Affairs, Oncology Business Unit, Eli Lilly and Company

Siddhartha Mukherjee, MD, DPhil, Assistant Professor of Medicine, Division of Oncology, Herbert Irving Comprehensive Cancer Center of Columbia University

Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs & Medical Director, Evelyn H. Lauder Breast Center, Memorial Sloan-Kettering Cancer Center

John E.L. Wong, MBBS, FAMS, FRCP, FACP, Isabel Chan Professor of Medical Sciences & Dean, The Yong Loo Lin School of Medicine, National University of Singapore; Director, The National University Cancer Institute, Singapore; Deputy Chief Executive, The National University Health System, Singapore

3:30 p.m.

BREAK

THURSDAY, APRIL 14, 2011 CONTINUED

4:00 p.m.

SESSION 4: Novel and Innovative Approaches to Clinical Trials of Cancer Therapies and Diagnostics

MODERATOR:

Oren J. Cohen, MD, Chief Medical & Scientific Officer, Quintiles Transnational Corp; Consulting Professor of Medicine, Duke University Medical Center

PANELISTS:

George Demetri, MD, Senior Vice President for Experimental Therapeutics, Dana-Farber Cancer Institute; Director, Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School

Keith T. Flaherty, MD, Director of Developmental Therapeutics, Massachusetts General Hospital Cancer Center

Lance Liotta, MD, Co-Director, Center for Applied Proteomics and Molecular Medicine, George Mason University

Mace L. Rothenberg, MD, Senior Vice President, Clinical Development and Medical Affairs, Pfizer Oncology

Nancy Simonian, MD, Chief Medical Officer, Millennium, The Takeda Oncology Company

5:30 p.m.

BREAK

6:00 p.m. – 10:00 p.m.

RECEPTION, DINNER & KEYNOTE

Rethinking the Goals of Cancer Therapy in the Age of Molecular Oncology

Riverpark, A Tom Colicchio Restaurant, at the Alexandria Center – New York City

KEYNOTE SPEAKER:

Craig Thompson, MD, President & Chief Executive Officer, Memorial Sloan-Kettering Cancer Center

FRIDAY, APRIL 15, 2011

8:30 a.m.

REGISTRATION

9:00 a.m.

SESSION 5: Advancing Innovation and Exploring New Directions in the Biotechnology and Pharmaceutical Industry

MODERATOR:

Robert Tepper, MD, Partner, Third Rock Ventures, LLC

PANELISTS:

Andreas Busch, PhD, BHC Member of the Executive Committee & Head of Global Drug Discovery, Bayer Healthcare AG

Chiang J. Li, MD, FACP, Chairman & Chief Executive Officer, Boston Biomedical, Inc.

Paolo Paoletti, MD, President, Oncology, GlaxoSmithKline

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, Inc.

William R. Sellers, MD, Vice President & Global Head of Oncology, Novartis Institutes for BioMedical Research

Jonathan M. Yingling, PhD, Vice President, Oncology Research, Lilly Research Laboratories, Eli Lilly and Company

10:30 a.m.

BREAK

11:00 a.m.

SESSION 6: New Frontiers in Oncology

MODERATOR:

Charles L. Sawyers, MD, Investigator, Howard Hughes Medical Institute; Chairman, Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

PANELISTS:

Daniel Haber, MD, PhD, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute

Prof. Sir David Lane, FRS, FRSE, FMedSci, Chief Scientist, Agency for Science Technology & Research, Singapore

Richard Scheller, PhD, Executive Vice President, Research & Early Development, Genentech, Inc.

Phillip A. Sharp, PhD, Institute Professor, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Bruce Stillman, PhD, FRS, President, Cold Spring Harbor Laboratory

FRIDAY, APRIL 15, 2011 CONTINUED

12:30 p.m.

LUNCH & KEYNOTE

A Comprehensive Review & The Path Forward

MODERATOR:

Dennis Gillings, CBE, PhD, Chairman & Chief Executive Officer, Quintiles Transnational Corp.

KEYNOTE SPEAKERS:

John Mendelsohn, MD, President, The University of Texas MD Anderson Cancer Center

Richard Scheller, PhD, Executive Vice President, Research & Early Development, Genentech, Inc.

Marc Tessier-Lavigne, PhD, President, The Rockefeller University

Craig Thompson, MD, President & Chief Executive Officer, Memorial Sloan-Kettering Cancer Center

2:00 p.m.

THE FUTURE OF CANCER THERAPIES AND DIAGNOSTICS: BIOTECHNOLOGY PIONEERS

MODERATORS:

Chau Q. Khuong, Private Equity Principal, OrbiMed Advisors, LLC

Joel S. Marcus, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments

Magnus Persson, MD, PhD, Managing Partner, The Column Group

Christian Plaza, Partner, Cooley LLP

BIOTECHNOLOGY PIONEERS:

Agios Pharmaceuticals, Inc., David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, Inc.

Aragon Pharmaceuticals, Inc., Richard Heyman, PhD, President & Chief Executive Officer, Aragon Pharmaceuticals, Inc.

Boston Biomedical, Inc., Chiang J. Li, MD, FACP, Chairman & Chief Executive Officer, Boston Biomedical, Inc.

Epizyme, Inc., Robert J. Gould, PhD, President and Chief Executive Officer, Epizyme, Inc.

Foundation Medicine, Inc., Alexis Borisy, Chief Executive Officer & Founder, Foundation Medicine, Inc.; Partner, Third Rock Ventures, LLC

Plexxikon Inc., K. Peter Hirth, PhD, Chief Executive Officer, Plexxikon Inc.

4:15 p.m.

CLOSING REMARKS

Lynne Zydowsky, PhD, President, Zydowsky Consultants LLC; Advisor, Alexandria Real Estate Equities, Inc.